Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunocore Holdings Plc ADR (NQ: IMCR )

31.52 +0.55 (+1.78%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immunocore Holdings Plc ADR

< Previous 1 2 Next >
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Institutions are Buying These 3 Stocks and Analysts Agree
Rumble (RUM), Immunocore (IMCR), and STMicroelectronics (STM) are attracting increased institutional interest, presenting potential investment opportunities. 
Via MarketBeat
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at the Bank of America Securities 2023 Health Care Conference
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at the 22nd Annual Needham Virtual Healthcare Conference
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present four posters at AACR Annual Meeting 2023
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore Reports 2022 Financial Results and Provides Business Update
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
From Immunocore Holdings Limited
Via GlobeNewswire
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore is awarded the Prix Galien France award for KIMMTRAK
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
From Immunocore Holdings Limited
Via GlobeNewswire
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. 
Via MarketBeat
Immunocore to present at the Jefferies London Healthcare Conference
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update
From Immunocore Holdings Limited
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.